Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects

Robert Vassar, Peer Hendrik Kuhn, Christian Haass, Matthew E. Kennedy, Lawrence Rajendran, Philip Chun Wong, Stefan F. Lichtenthaler

Research output: Contribution to journalArticle

Abstract

The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane aspartyl proteases cleaving the amyloid precursor protein (APP). BACE1 is a major drug target for Alzheimer's disease because BACE1-mediated cleavage of APP is the first step in the generation of the pathogenic amyloid-β peptides. BACE1, which is highly expressed in the nervous system, is also required for myelination by cleaving neuregulin 1. Several recent proteomic and in vivo studies using BACE1- and BACE2-deficient mice demonstrate a much wider range of physiological substrates and functions for both proteases within and outside of the nervous system. For BACE1 this includes axon guidance, neurogenesis, muscle spindle formation, and neuronal network functions, whereas BACE2 was shown to be involved in pigmentation and pancreatic β-cell function. This review highlights the recent progress in understanding cell biology, substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)4-28
Number of pages25
JournalJournal of Neurochemistry
Volume130
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Cytology
Amyloid beta-Protein Precursor
Cell Biology
Peptide Hydrolases
Nervous System
Alzheimer Disease
Neurology
Neuregulin-1
Aspartic Acid Proteases
Muscle Spindles
Neurogenesis
Pigmentation
Amyloid
Proteomics
Substrates
Therapeutics
Muscle
Peptides
Enzymes
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • BACE1
  • BACE2
  • protease
  • regulated intramembrane proteolysis
  • secretase

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Vassar, R., Kuhn, P. H., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014). Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects. Journal of Neurochemistry, 130(1), 4-28. https://doi.org/10.1111/jnc.12715

Function, therapeutic potential and cell biology of BACE proteases : Current status and future prospects. / Vassar, Robert; Kuhn, Peer Hendrik; Haass, Christian; Kennedy, Matthew E.; Rajendran, Lawrence; Wong, Philip Chun; Lichtenthaler, Stefan F.

In: Journal of Neurochemistry, Vol. 130, No. 1, 2014, p. 4-28.

Research output: Contribution to journalArticle

Vassar, R, Kuhn, PH, Haass, C, Kennedy, ME, Rajendran, L, Wong, PC & Lichtenthaler, SF 2014, 'Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects', Journal of Neurochemistry, vol. 130, no. 1, pp. 4-28. https://doi.org/10.1111/jnc.12715
Vassar, Robert ; Kuhn, Peer Hendrik ; Haass, Christian ; Kennedy, Matthew E. ; Rajendran, Lawrence ; Wong, Philip Chun ; Lichtenthaler, Stefan F. / Function, therapeutic potential and cell biology of BACE proteases : Current status and future prospects. In: Journal of Neurochemistry. 2014 ; Vol. 130, No. 1. pp. 4-28.
@article{772ea72ddc934c6d9cd4bb73a78cd5b4,
title = "Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects",
abstract = "The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane aspartyl proteases cleaving the amyloid precursor protein (APP). BACE1 is a major drug target for Alzheimer's disease because BACE1-mediated cleavage of APP is the first step in the generation of the pathogenic amyloid-β peptides. BACE1, which is highly expressed in the nervous system, is also required for myelination by cleaving neuregulin 1. Several recent proteomic and in vivo studies using BACE1- and BACE2-deficient mice demonstrate a much wider range of physiological substrates and functions for both proteases within and outside of the nervous system. For BACE1 this includes axon guidance, neurogenesis, muscle spindle formation, and neuronal network functions, whereas BACE2 was shown to be involved in pigmentation and pancreatic β-cell function. This review highlights the recent progress in understanding cell biology, substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer's disease.",
keywords = "Alzheimer's disease, BACE1, BACE2, protease, regulated intramembrane proteolysis, secretase",
author = "Robert Vassar and Kuhn, {Peer Hendrik} and Christian Haass and Kennedy, {Matthew E.} and Lawrence Rajendran and Wong, {Philip Chun} and Lichtenthaler, {Stefan F.}",
year = "2014",
doi = "10.1111/jnc.12715",
language = "English (US)",
volume = "130",
pages = "4--28",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Function, therapeutic potential and cell biology of BACE proteases

T2 - Current status and future prospects

AU - Vassar, Robert

AU - Kuhn, Peer Hendrik

AU - Haass, Christian

AU - Kennedy, Matthew E.

AU - Rajendran, Lawrence

AU - Wong, Philip Chun

AU - Lichtenthaler, Stefan F.

PY - 2014

Y1 - 2014

N2 - The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane aspartyl proteases cleaving the amyloid precursor protein (APP). BACE1 is a major drug target for Alzheimer's disease because BACE1-mediated cleavage of APP is the first step in the generation of the pathogenic amyloid-β peptides. BACE1, which is highly expressed in the nervous system, is also required for myelination by cleaving neuregulin 1. Several recent proteomic and in vivo studies using BACE1- and BACE2-deficient mice demonstrate a much wider range of physiological substrates and functions for both proteases within and outside of the nervous system. For BACE1 this includes axon guidance, neurogenesis, muscle spindle formation, and neuronal network functions, whereas BACE2 was shown to be involved in pigmentation and pancreatic β-cell function. This review highlights the recent progress in understanding cell biology, substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer's disease.

AB - The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane aspartyl proteases cleaving the amyloid precursor protein (APP). BACE1 is a major drug target for Alzheimer's disease because BACE1-mediated cleavage of APP is the first step in the generation of the pathogenic amyloid-β peptides. BACE1, which is highly expressed in the nervous system, is also required for myelination by cleaving neuregulin 1. Several recent proteomic and in vivo studies using BACE1- and BACE2-deficient mice demonstrate a much wider range of physiological substrates and functions for both proteases within and outside of the nervous system. For BACE1 this includes axon guidance, neurogenesis, muscle spindle formation, and neuronal network functions, whereas BACE2 was shown to be involved in pigmentation and pancreatic β-cell function. This review highlights the recent progress in understanding cell biology, substrates, and functions of BACE proteases and discusses the therapeutic options and potential mechanism-based liabilities, in particular for BACE inhibitors in Alzheimer's disease.

KW - Alzheimer's disease

KW - BACE1

KW - BACE2

KW - protease

KW - regulated intramembrane proteolysis

KW - secretase

UR - http://www.scopus.com/inward/record.url?scp=84903190262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903190262&partnerID=8YFLogxK

U2 - 10.1111/jnc.12715

DO - 10.1111/jnc.12715

M3 - Article

C2 - 24646365

AN - SCOPUS:84903190262

VL - 130

SP - 4

EP - 28

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 1

ER -